Form 4: Guardant Health CLO Reports RSU Vesting & Tax Withholding

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported transactions on December 15, 2025.
• Saia acquired 1,020 shares of Common Stock through the vesting of restricted stock units (RSUs).
• Following the acquisition, Saia's direct beneficial ownership of Common Stock was 44,192 shares.
• Concurrently, 535 shares of Common Stock were disposed of by the company at a price of $102.67 per share to satisfy tax withholding obligations related to the RSU vesting.
• After these transactions, Saia's direct beneficial ownership of Common Stock stands at 43,657 shares.
• The reported RSU award was granted on June 9, 2023, with 33% vesting on June 15, 2024, and the remaining 67% vesting in equal quarterly installments over the subsequent two-year period.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction related to executive compensation and tax obligations, which is neutral in terms of company performance or strategic direction.

Positives

• The vesting of 1,020 restricted stock units indicates continued compensation and retention of a key executive, John G. Saia.
• The transaction is a routine part of executive compensation, reflecting the fulfillment of previously granted equity awards.

Negatives

• A disposition of 535 shares occurred to cover tax withholding, which reduces the executive's direct ownership in the company, albeit for a non-discretionary purpose.

Risks

• The value of the remaining beneficially owned shares is subject to market fluctuations inherent in holding public company stock.

Future Outlook

The remaining 67% of the restricted stock unit award, granted on June 9, 2023, is scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024.

Management Comments

• The reported transactions are a standard component of the Chief Legal Officer's equity compensation plan, involving the vesting of restricted stock units and the subsequent mandatory sale of shares to cover tax liabilities.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies, reflecting the standard process of executive equity compensation and tax compliance. It does not provide specific insights into broader industry trends or competitive positioning beyond the company's ongoing executive compensation practices.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a significant change in the company's financial health or strategic direction. The reduction in direct ownership due to tax withholding is minor.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Continued vesting of the remaining 67% of the restricted stock unit award in equal quarterly installments over the next two years.

Key Dates

Keywords

Guardant Health, GH, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, John G. Saia, Chief Legal Officer, Equity Compensation